- Home
- BEEM vs QTTB Comparison
BEEM vs QTTB Comparison
Compare BEEM & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEEM
- QTTB
- Stock Information
- Founded
- BEEM 2006
- QTTB 2015
- Country
- BEEM United States
- QTTB United States
- Employees
- BEEM N/A
- QTTB N/A
- Industry
- BEEM Semiconductors
- QTTB Biotechnology: Pharmaceutical Preparations
- Sector
- BEEM Technology
- QTTB Health Care
- Exchange
- BEEM Nasdaq
- QTTB Nasdaq
- Market Cap
- BEEM 21.7M
- QTTB 19.0M
- IPO Year
- BEEM N/A
- QTTB N/A
- Fundamental
- Price
- BEEM $1.96
- QTTB $1.65
- Analyst Decision
- BEEM Strong Buy
- QTTB Hold
- Analyst Count
- BEEM 3
- QTTB 8
- Target Price
- BEEM $9.00
- QTTB $24.00
- AVG Volume (30 Days)
- BEEM 123.6K
- QTTB 185.5K
- Earning Date
- BEEM 05-23-2025
- QTTB 05-08-2025
- Dividend Yield
- BEEM N/A
- QTTB N/A
- EPS Growth
- BEEM N/A
- QTTB N/A
- EPS
- BEEM N/A
- QTTB N/A
- Revenue
- BEEM $49,336,000.00
- QTTB N/A
- Revenue This Year
- BEEM $27.41
- QTTB N/A
- Revenue Next Year
- BEEM $58.00
- QTTB N/A
- P/E Ratio
- BEEM N/A
- QTTB N/A
- Revenue Growth
- BEEM N/A
- QTTB N/A
- 52 Week Low
- BEEM $1.33
- QTTB $1.38
- 52 Week High
- BEEM $7.68
- QTTB $53.79
- Technical
- Relative Strength Index (RSI)
- BEEM 65.82
- QTTB 45.84
- Support Level
- BEEM $1.40
- QTTB $1.49
- Resistance Level
- BEEM $1.48
- QTTB $1.63
- Average True Range (ATR)
- BEEM 0.09
- QTTB 0.15
- MACD
- BEEM 0.09
- QTTB 0.02
- Stochastic Oscillator
- BEEM 93.33
- QTTB 38.94
About BEEM Beam Global
Beam Global produces sustainable technology for electric vehicle (EV) charging, outdoor media, and energy security, without the construction, disruption, and costs of grid-tied solutions. Its products are founded upon its patented EV ARC and Solar Treelines and include BeamTrak patented solar tracking, and ARC Technology energy storage, along with EV charging, outdoor media, and disaster preparedness packages. From start to finish, the company develops, patents, designs, engineers, and manufactures renewably energized products that help the environment, empower communities, and keep people moving.
About QTTB Q32 Bio Inc. Common Stock
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.